Combination of aripiprazole and ethanol attenuates marble-burying behavior in mice

Acta Poloniae Pharmaceutica - Drug Research

Volumn 68, Issue 3, 2011, Pages 435-440

  Gaikwad, Uday ^a   Parle, Milind ^a  

^a GURU JAMBHESHWAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

Author keywords

Aripiprazole; Ethanol; Marble burying behavior

Indexed keywords

ALCOHOL; ARIPIPRAZOLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; EVOKED RESPONSE; LOCOMOTION; LOW DRUG DOSE; MALE; MARBLE BURYING BEHAVIOR; MOTOR PERFORMANCE; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETHANOL; MALE; MICE; MOTOR ACTIVITY; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; QUINOLONES;

EID: 79956330319     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., et al.: Am. J. Hum. Genet. 78, 815 (2006).
2. Parle M., Gaikwad U.: Int. J. Med. Sci. 2, 84 (2009).
3. Parle M., Gaikwad U.: Asian. J. BioSci. 4, 120 (2009).
4. Poling A., Cleary J., Monaghan M.: J. Exp. Anal. Behav. 35, 31 (1981).
5. Archer T., Fredriksson A., Lewander T., Soderberg U.: Scand. J. Psychol. 28, 242 (1987).
6. Millan M.J., Dekeyne A., Papp M., La Rochelle C.D., MacSweeny C., Peglion J.L., Brocco M.: J. Pharmacol. Exp. Ther. 298, 581 (2001).
7. Broekkamp C.L., Rijk H.W., Joly-Gelouin D., Lloyd K.L.: Eur. J. Pharmacol. 126, 223 (1986).
8. Gyertyan I.: Behav. Pharmacol. 6, 24 (1995).
9. Naber D., Lambert M.: Prog. Neuropsychopharmacol. Biol. Psychiatry. 28, 1213 (2004).
10. Little H.J.: Addiction 95, 1751 (2000).
11. Phillips T.J., Shen E.H., McKinnon C.S., Burkhart-Kasch S., Lessov C.N., Palmer A.A.: Ethanol Clin. Exp. Res. 26, 593 (2002).
12. Gaikwad U., Bhutada P., Wanjari M., Umathe S.: Eur. J. Pharmacol. 563, 155 (2007).
13. Rapoport J.L., Leonard H.L., Swedo S.E., Lenane M.C.: J. Clin. Psychiatry 54 Suppl., 27 (1993).
14. Rapoport J.L.: J. Am. Med. Assoc. 260, 2888 (1988).
15. Leite J.V., Guimarǎes F.S., Moreira F.A.: Eur. J. Pharmacol. 578, 222 (2008).
16. Correa M., Manrique H.M., Font L., Escrig M.A., Aragon C.M.: Psychopharmacology (Berl) 200, 455 (2008).
17. Hirose T., Kikuchi T.: J. Med. Invest. 52 Suppl., 284 (2005).
18. Lieberman J.A.: CNS Drugs 18, 251 (2004).
19. Kushner M., Sher K., Beitman B.: Am. J. Psychiatry 147, 685 (1990).
20. Correa M., Arizzi M.N., Betz A., Mingote S., Salamone J.D.: Brain Res. Bull. 62, 197 (2003).
21. Tambour S., Didone V., Tirelli E., Quertemont E.: Eur. Neuropsychopharmacol. 15, 655 (2005).
22. Koran L.M., Gamel N.N., Choung H.W., Smith E.H., Aboujaoude E.N.: J. Clin. Psychiatry 66, 515 (2005).
23. Roth B.: Ann. Clin. Psychiatry 6, 67 (1994).
24. Costall B., Naylor R.: Br. J. Pharmacol. 116, 2989 (1995).
25. Van De Kar L.D., Javed A., Zhang Y., Serres F., Raap D., Gray T.: J. Neurosci. 21, 3572 (2001).